Friday, June 10, 2016

Share Your Experience with LDN To Move Research Forward

I received an e-mail today from the LDN Research Trust (LDN = low-dose naltrexone):
"The National Institute of Health in the USA which is the body that grants funds for public research into ME/CFS has put out a "Request for Information: Soliciting Input for New Research Strategies for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)"

They are asking for ideas from individuals as well as bigger groups. The response date is by 24th June so we need to act quickly!

The request can be found at this NIH link.

If you have any experience of LDN for ME/CFS as a user or prescriber please send an email to MECFSRFI@mail.nih.govMECFSRFI@mail.nih.gov Your input would be invaluable."





Low-dose naltrexone (LDN) is a treatment used for all kinds of immune disorders, including ME/CFS, to help normalize the immune system. It is extremely safe, as it is a medication that has been used in large doses of 50 mg (or much more) for many decades, and for this purpose, it is used in tiny doses of only 0.5 mg - 4.5 mg.

My son and I have had great success with LDN. I felt better - with more energy and less fatigue - the very first day after my first bedtime dose! Many people take a bit longer than that, with some trial and error, to find just the right dose for them, but it is a treatment that has helped many people with ME/CFS. For more on our experiences and links to more information on LDN, check out this past LDN blog post.

Please take a moment to use the e-mail link above to share your positive experiences with using LDN for ME/CFS - there have been many dozens of studies proving its effectiveness for many immune disorders, but - no surprise - not a single study yet on LDN and ME/CFS.

Remember the deadline is June 24!

No comments:

Post a Comment